News | July 28, 2023
Laurus Labs posts decline in Q1FY24 consolidated PAT to Rs. 24.85 Cr
The company has reported total income of Rs. 1185.39 crores during the period ended June 30, 2023
The company has reported total income of Rs. 1185.39 crores during the period ended June 30, 2023
Dr. Lal Path Labs Ltd. has reported total income of Rs. 555.4 crores during the period ended June 30, 2023
The company has reported total income of Rs. 1052.79 crores during the period ended June 30, 2023
Cipla has reported total income of Rs. 6465.18 crores during the period ended June 30, 2023
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Jubilant Ingrevia has reported total income of Rs. 1083.52 crores during the period ended June 30, 2023
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock
Subscribe To Our Newsletter & Stay Updated
